Company
Headquarters: Chennai, India
Employees: 1,675
₹166.86 Billion
INR as of Jan. 1, 2025
US$1.95 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Caplin Point Laboratories Limited develops, produces, markets, and exports generic pharmaceutical formulations and branded products in India. The company provides liquid and lyophilized injections, ophthalmic products, tablets, liquid orals, capsules, softgel capsules, suppositories and ovules, powder for injection, dry syrups, topicals, inhalers, IV infusions, lyophilized products, branded products, dermo cosmetics, and other products. It also operates QueTenX, an e-commerce website. The company was incorporated in 1990 and is headquartered in Chennai, India.
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | ₹18.33 B |
| EBITDA | ₹6.76 B |
| Gross Profit TTM | ₹10.45 B |
| Profit Margin | 26.93% |
| Operating Margin | 30.64% |
| Quarterly Revenue Growth | 17.80% |
Caplin Point Laboratories Ltd has the following listings and related stock indices.
Stock: NSE: CAPLIPOINT wb_incandescent
Stock: BSE: CAPPL wb_incandescent